Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
30 studies found for:    Transverse Myelitis
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Condition: Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Intervention: Drug: SA237
22 Recruiting A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
Interventions: Biological: MEDI-551;   Other: Placebo
23 Recruiting Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorders
Intervention: Drug: Mitoxantrone
24 Recruiting Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Procedure: AHSCT
25 Completed
Has Results
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Devic's Disease
Intervention: Drug: Eculizumab
26 Not yet recruiting Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention: Biological: Tolerogenic Dendritic cells loaded with myelin peptides
27 Recruiting Hematopoietic Stem Cell Transplant in Devic's Disease
Condition: Devic's Disease
Intervention: Procedure: Hematopoietic stem cell transplantation
28 Recruiting Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
Conditions: Devic's Syndrome;   Devic's Neuromyelitis Optica;   Devic Syndrome;   Devic's Disease;   Devic Disease
Intervention: Biological: Autologous mesenchymal stem cells
29 Recruiting Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01
30 Recruiting Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
Conditions: Neuromyelitis Optica (NMO);   NMO Spectrum Disorder (NMOSD)
Intervention: Drug: SA237

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page   
Indicates status has not been verified in more than two years